阿替利珠单抗治疗铂类经治局部晚期或转移性尿路上皮癌:美国扩展可及性研究临床经验
该单臂开放标签扩展可及性研究纳入218例铂类经治的局部晚期或转移性尿路上皮癌患者,评估阿替利珠单抗的疗效与安全性。114例可评估患者中客观缓解率为15%,疾病控制率为49%,安全性特征与既往研究一致。
要点
- 铂类经治mUC患者中阿替利珠单抗客观缓解率15%,疾病控制率49%。
- 基线57%患者ECOG PS≥1,19%血红蛋白<10g/dl,25%肝转移。
- 治疗相关不良事件见于214例中98例,以疲乏为主。
核心结论
- 尽管存在既往治疗和不良预后因素,阿替利珠单抗的获益/风险特征与既往研究一致。
- 结果提示阿替利珠单抗可能适用于比典型1-3期研究更广泛的患者人群。
研究设计与样本
- 单臂、开放标签扩展可及性研究,在美国36个中心入组218例患者。
- 关键入组标准:mUC铂类化疗期间/后进展或围手术期12个月内进展,ECOG PS 0-2。
- 干预:阿替利珠单抗1200mg静脉每3周一次,直至失去临床获益、不可接受毒性、撤回知情、决定停药、死亡、商业可及或研究关闭。
主要发现
- 全部患者均接受过既往全身治疗(68%为mUC,27%辅助,26%新辅助)。
- 214例治疗患者中,基线57% ECOG PS≥1,19%血红蛋白<10g/dl,25%肝转移。
- 中位治疗持续时间9周(IQR 6-12周)。
- 中位随访时间总体2.3个月(IQR 1.6-3.4),已知未死亡患者2.7个月(IQR 2.0-3.5)。
关键数值与推荐
- 客观缓解率采用RECIST v1.1评估。
- 疾病控制率定义为缓解或疾病稳定。
临床怎么用
- 对于铂类经治的局部晚期或转移性尿路上皮癌患者,阿替利珠单抗是可考虑的治疗选择。
- 治疗期间需监测治疗相关不良事件,常见为疲乏。
局限性
- 单臂设计,无对照组。
- 中位随访时间较短(总体2.3个月)。
- 可评估疗效患者仅114例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atezolizumab (anti-programmed death-ligand 1) was approved in the USA, Europe, and elsewhere for treatment-naive and platinum-treated locally advanced/metastatic urothelial carcinoma (mUC). OBJECTIVE: To report efficacy and safety from an atezolizumab expanded access study. DESIGN, SETTING, AND PARTICIPANTS: This single-arm, open-label study enrolled 218 patients at 36 US sites. Key eligibility criteria included progression during/following ≥1 platinum-based chemotherapy for mUC or in perioperative setting (progression within 12 mo) and Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2. INTERVENTION: Patients received atezolizumab1200mg intravenously every 3 wk until loss of clinical benefit, unacceptable toxicity, consent withdrawal, decision to discontinue, death, atezolizumab commercial availability, or study closure. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Key end points reported herein included Response Evaluation Criteria in Solid Tumors v1.1 objective response rate and duration, disease control rate (DCR; response or stable disease), and safety. RESULTS AND LIMITATIONS: All patients received prior systemic therapy (68% mUC; 27% adjuvant; and 26% neoadjuvant). At baseline, 57% of 214 treated patients had ECOG PS ≥1, 19% had hemoglobin <10g/dl, and 25% had liver metastases. Median treatment duration was 9 wk (interquartile range [IQR], 6-12 wk). Median follow-up duration was 2.3 mo (IQR, 1.6-3.4 mo) overall and 2.7 mo (IQR, 2.0-3.5 mo) in patients not known to have died. Seventeen of 114 evaluable patients (15%) had objective responses (16 ongoing at study termination). DCR was 49%. Treatment-related adverse events (mostly fatigue) occurred in 98 of 214 treated patients. CONCLUSIONS: The benefit/risk profile of atezolizumab was consistent with that observed in previous studies, despite pretreatment and poor prognostic factors. These results suggest a potential role for atezolizumab in a broader patient range than typically eligible for phase 1-3 studies. PATIENT SUMMARY: In this expanded access study, atezolizumab was active and tolerable in a range of patients with platinum-treated metastatic urothelial carcinoma.
引用
- Pal SK, Hoffman-Censits J, Zheng H, et al. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States. Eur Urol. 2018. PMID: 29478735. doi:10.1016/j.eururo.2018.02.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。